Danaher Corporation $DHR Shares Bought by Spear Holdings RSC Ltd

Key Points

• Spear Holdings RSC Ltd has increased its stake in Danaher Corporation by 50.6%, now owning approximately 409,384 shares valued at around $80.87 million.
• Institutional investors hold 79.05% of Danaher's stock, indicating strong institutional interest in the company.
• Danaher recently announced a quarterly dividend of $0.32 per share, which will be paid at the end of October, representing a 0.6% dividend yield.

Spear Holdings RSC Ltd increased its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 50.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 409,384 shares of the conglomerate's stock after acquiring an additional 137,484 shares during the period. Danaher comprises about 5.9% of Spear Holdings RSC Ltd's portfolio, making the stock its 6th largest position. Spear Holdings RSC Ltd owned about 0.06% of Danaher worth $80,870,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nuveen LLC bought a new stake in shares of Danaher in the first quarter valued at about $833,941,000. Invesco Ltd. raised its position in Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after buying an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. lifted its stake in Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock valued at $295,550,000 after acquiring an additional 1,072,617 shares in the last quarter. Generation Investment Management LLP boosted its position in Danaher by 33.2% during the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate's stock worth $651,515,000 after acquiring an additional 791,662 shares during the last quarter. Finally, Parnassus Investments LLC grew its stake in shares of Danaher by 23.3% during the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate's stock worth $784,745,000 after acquiring an additional 722,636 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 11.10% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on DHR shares. UBS Group reduced their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Bank of America cut their price target on shares of Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research report on Monday, September 22nd. Wells Fargo & Company decreased their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Robert W. Baird upped their target price on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Danaher in a research report on Saturday, September 27th. Seventeen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $245.91.

Danaher Stock Performance

NYSE DHR opened at $211.65 on Tuesday. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.41. The stock has a market cap of $151.55 billion, a PE ratio of 45.03, a P/E/G ratio of 3.06 and a beta of 0.77. The firm has a 50-day moving average of $200.36 and a 200-day moving average of $197.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period last year, the business posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher's dividend payout ratio (DPR) is currently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.